Following a full submission
AWMSG advice |
|||
| Status: Recommended | |||
Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®) is recommended as an option for use within NHS Wales as treatment for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy. |
|||
|
|||
Medicine details |
|||
| Medicine name | delta-9-tetrahydrocannabinol/cannabidiol (Sativex®) | ||
| Formulation | 2.7 mg / 2.5mg oromucosal spray | ||
| Reference number | 644 | ||
| Indication | Treatment for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy |
||
| Company | Bayer Healthcare Pharmaceuticals | ||
| BNF chapter | Musculoskeletal & joint diseases | ||
| Submission type | Full | ||
| Status | Recommended | ||
| Advice number | 1814 | ||
| NMG meeting date | 18/06/2014 | ||
| AWMSG meeting date | 16/07/2014 | ||
| Ratification by Welsh Government | 13/08/2014 | ||
| Date of issue | 14/08/2014 | ||
| Date of last review | 31/10/2017 | ||